Onderneming Biodexa Pharmaceuticals Plc London S.E.
Aandelen
BDRX
GB00BNGF1L75
Biotechnologie & Medisch Onderzoek
Vakgebied
Aantal werknemers: 21
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pipeline Research and Development
100,0
%
| 1 | 100,0 % | 0 | 100,0 % | -44,99% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Belgium
100,0
%
| 1 | 100,0 % | 0 | 100,0 % | -44,99% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 44 | 11-07-21 | |
Steve Ellul
PRN | Corporate Officer/Principal | - | 01-02-22 |
Fiona Sharp
AUD | Comptroller/Controller/Auditor | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 20-06-22 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 29-10-14 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Simon Turton
BRD | Director/Board Member | 56 | 08-12-14 |
Ann Merchant
BRD | Director/Board Member | 59 | 31/12 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 400 | 67 714 | 39 217 ( 57,92 %) | 0 | 57,92 % |
Bedrijfsgegevens
Biodexa Pharmaceuticals Plc
1 Caspian Point Caspian Way
CF10 4DQ, Cardiff
+44 29 2048 0180
http://www.midatechpharma.comBedrijven van de groep
Naam | Categorie en sector |
---|---|
Midatech Pharma España SL
Midatech Pharma España SL Pharmaceuticals: MajorHealth Technology Part of Biodexa Pharmaceuticals Plc, Midatech Pharma España SL is a pharmaceutical company located in Spain. The Spanish company operates in the field of oncology and other areas. |
Pharmaceuticals: Major
|
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,73 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |